Metropolis Healthcare Limited — Updates, 04-02-2025: Press Release

Metropolis Healthcare reported a strong performance in Q3 FY25, with a profit after tax (PAT) of ₹31 Cr, reflecting a 15.3% year-over-year increase. Revenue from operations reached ₹323 Cr, up 10.9% compared to the previous year, while EBITDA grew to ₹72 Cr, representing a 9.4% increase. The company achieved robust growth in both B2C and B2B segments, with B2C revenues rising by 15% year-over-year and B2B revenues increasing by 10% for the third consecutive quarter. Notably, the TruHealth segment contributed significantly, with a 25% growth in revenue, while specialty revenue grew by 13%. Metropolis continues to focus on high-value offerings and expanding its footprint, particularly in North India, through strategic acquisitions and enhanced service delivery capabilities. This positive momentum underscores the company’s commitment to innovation and customer experience within the evolving diagnostics landscape. Investors should watch closely for future growth in both existing and new market segments.